[1] Gines P,Quintero E,Arroyo V,et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology,1987,7（1）:122-128.
[2] Asrani S K,Larson J J,Yawn B,et al. Underestimation of liver-related mortality in the United States. Gastroenterology,2013,145（2）:375-82.e1-2.
[3] Planas R,Montoliu S,Balleste B,et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol,2006,4（11）:1385-1394.
[4] Runyon B A,Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology,2013,57（4）:1651-1653.
[5] Serste T,Francoz C,Durand F,et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites:a cross-over study. J Hepatol,2011,55（4）:794-799.
[6] Serste T,Melot C,Francoz C,et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology,2010,52（3）:1017-1022.
[7] Ge P S,Runyon B A. When should the β-blocker window in cirrhosis close. Gastroenterology,2014,146（7）:1597-1599.
[8] Krag A,Wiest R,Albillos A,et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut,2012,61（7）:967-969.
[9] Singh V,Dhungana S P,Singh B,et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites:a randomized pilot study. J Hepatol,2012,56（2）:348-354.
[10] Misra V L,Vuppalanchi R,Jones D,et al. The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. Aliment Pharmacol Ther,2010,32（8）:1044-1050.
[11] Kalambokis G,Tsianos E V. Midodrine and furosemide-induced natriuresis in cirrhotics with ascites. Aliment Pharmacol Ther, 2011,33（3）:415-416.
[12] Hamdy H,ElBaz A A,Hassan A,et al. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients:a randomized pilot study. J Clin Gastroenterol,2014,48（2）:184-188.
[13] Arroyo V,García-Martinez R,Salvatella X. Human serum albumin,systemic inflammation,and cirrhosis. J Hepatol,2014,61（2）:396-407.
[14] Garcia-Martinez R,Andreola F,Mehta G,et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. J Hepatol,2014[ahead of print].
[15] Wong C L,Holroyd-Leduc J,Thorpe K E,et al. Does this patient have bacterial peritonitis or portal hypertension How do I perform a paracentesis and analyze the results. JAMA,2008,299（10）:1166-1178.
[16] Bernardi M,Caraceni P,Navickis R J,et al. Albumin infusion in patients undergoing large-volume paracentesis:a meta-analysis of randomized trials. Hepatology,2012,55（4）:1172-1181.
[17] Nakamura T,Sata M,Suzuki K,et al. Open-labeled randomized controlled trial to compare diuretic therapy with recombinant human serum albumin and diuretic therapy for therapeutic treatment of ascites in patients with advanced liver cirrhosis: An exploratory trial. Hepatol Res,2014,44（5）:502-514.
[18] Gassanov N,Semmo N,Semmo M,et al. Arginine vasopressin （AVP）and treatment with arginine vasopressin receptor antagonists（vaptans） in congestive heart failure,liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion（SIADH）. Eur J Clin Pharmacol,2011,67（4）:333-346.
[19] Dahl E,Gluud L L,Kimer N,et al. Meta-analysis:the safety and efficacy of vaptans（tolvaptan,satavaptan and lixivaptan）in cirrhosis with ascites or hyponatraemia. Aliment Pharmacol Ther,2012,36（7）:619-626.
[20] Kwo P Y. Management of hyponatremia in clinical hepatology practice. Curr Gastroenterol Rep,2014,16（5）:382.
[21] EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis. J Hepatol,2010,53（3）:397-417.
[22] Salerno F,Gerbes A,Gines P,et al. Diagnosis,prevention and treatment of hepatorenal syndrome in cirrhosis. Gut,2007,56（9）:1310-1318.
[23] Gluud L L,Christensen K,Christensen E,et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology,2010,51（2）:576-584.
[24] Sagi S V,Mittal S,Kasturi K S,et al. Terlipressin therapy for reversal of type 1 hepatorenal syndrome:a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol,2010,25（5）:880-885.
[25] Lotte G L,Kurt C,Erik C,et al. Terlipressin for hepatorenal syndrome. Cochrane Database of Systematic Reviews,2012（9）:312.
[26] Cheong H S,Kang C I,Lee J A,et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis,2009,48（9）: 1230-1236.
[27] Wiest R,Krag A,Gerbes A. Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut,2012,61（2）:297-310.
[28] Hoban D J,Bouchillon S K,Hawser S P,et al. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States,2007-2008:results of the Study for Monitoring Antimicrobial Resistance Trends（SMART）. Antimicrob Agents Chemother,2010,54（7）:3031-3034.
[29] Terg R,Fassio E,Guevara M,et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis:a randomized, placebo-controlled study. J Hepatol,2008,48（5）:774-779.
[30] Fernandez J,Navasa M,Planas R,et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology,2007,133（3）:818-824. |
